Sangamo Therapeutics (SGMOQ) Liabilities and Shareholders Equity (2010 - 2025)

Sangamo Therapeutics' Liabilities and Shareholders Equity history runs 16 years deep, the most recent figure standing at $59.7 million for Q4 2025.

• In Q4 2025, Liabilities and Shareholders Equity fell 41.22% year-over-year to $59.7 million; the TTM figure through Dec 2025 stood at $332.1 million (down 23.63% YoY), while the FY2025 annual figure was $59.7 million, down 41.22% from the prior year.
• Liabilities and Shareholders Equity for Q4 2025 stood at $59.7 million, down from $88.6 million in the prior quarter.
• The five-year high for Liabilities and Shareholders Equity was $877.1 million in Q1 2021, with the low at $59.7 million in Q4 2025.
• The 5-year median for Liabilities and Shareholders Equity is $272.4 million (2023), against an average of $377.6 million.
• The sharpest annual moves came in 2021 and 2024: Liabilities and Shareholders Equity jumped 50.12% in 2021, then plunged 71.39% in 2024.
• Sangamo Therapeutics' Liabilities and Shareholders Equity stood at $721.9 million in 2021, then fell by 22.08% to $562.5 million in 2022, then tumbled by 70.61% to $165.3 million in 2023, then tumbled by 38.52% to $101.6 million in 2024, then slumped by 41.22% to $59.7 million in 2025.
• Business Quant data shows SGMOQ's Liabilities and Shareholders Equity at $59.7 million in Q4 2025, $88.6 million in Q3 2025, and $97.6 million in Q2 2025.